Choose Your Country or Region

JAK

Choose Selective JAK Inhibitors

JAK Signaling Pathway Map

Isoform-selective Inhibitors

JAK Products

All (65)
JAK Inhibitors (64)
JAK Antibodie (1)
New JAK Products

Catalog No.	Product Name	Information	Product Use Citations
E0011^New	Linderalactone	Linderalactone inhibits human lung cancer growth by modulating the expression of apoptosis-related proteins (Bax and Bcl-2) with an IC50 of 15 µM in A-549 cells. Linderalactone induces G2/M cell cycle arrest and could also suppress the JAK/STAT signalling pathway. Linderalactone can be isolated from Radix linderae.
S0374	GDC046	GDC046 (Compound 3) is a potent, selective, and orally bioavailable inhibitor of TYK2 with Ki of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM for TYK2, JAK1, JAK2, and JAK3, respectively.
S0384	RO495	RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).
S0391	TG-89	TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM.
S0437	SAR-20347	SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling.
S0871	Gusacitinib (ASN-002)	Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
S0918	Ginkgolic acid C17:1	Ginkgolic acid C17:1 (GAC 17:1) inhibits constitutive activation of STAT3 through the abrogation of upstream JAK2 and Src. Ginkgolic acid C17:1 can induce the substantial expression of PTEN and SHP-1. Ginkgolic acid C17:1 induces apoptosis of tumor cells.
S0981	BD750	BD750 is an immunosuppressant and a dual inhibitor of JAK3 and STAT5 that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.5 μM and 1.1 μM for mouse and human T-cell proliferation, respectively.
S1134	AT9283	AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM in cell-free assays; also potent to Aurora A/B, Abl1(T315I). Phase 2.	Sci Rep, 2022, 12(1):7 Mol Syst Biol, 2021, 17(9):e10426 Cancers (Basel), 2021, 13(6)1205
S1143	AG-490 (Tyrphostin B42)	AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.	Nat Commun, 2021, 12(1):6891 Cell Mol Life Sci, 2021, 10.1007/s00018-021-03997-2 Front Oncol, 2021, 11:650052
S1378	Ruxolitinib (INCB018424)	Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.	Blood, 2022, blood.2021012366 Mol Neurodegener, 2022, 17(1):7 J Exp Clin Cancer Res, 2022, 41(1):10
S2162	AZD1480	AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.	Mol Neurodegener, 2022, 17(1):7 Sci Rep, 2022, 12(1):7 Immunity, 2021, 54(11):2514-2530.e7
S2179	Gandotinib (LY2784544)	Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.	Sci Rep, 2022, 12(1):7 BMC Cancer, 2021, 21(1):1213 Molecules, 2021, 26(3)606
S2214	AZ 960	AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and K_i of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3. AZ 960 induces apoptosis and growth arrest.	BMC Cancer, 2021, 21(1):1213 Carcinogenesis, 2020, 41(7):993-1004 Nat Commun, 2019, 10(1):716
S2219	Momelotinib (CYT387)	Momelotinib (CYT387, LM-1149 , CYT11387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Momelotinib (CYT387) induces apoptosis and autophagy. Phase 3.	Cell Stem Cell, 2021, S1934-5909(21)00344-1 Cancer Res, 2021, canres.0955.2021 J Transl Med, 2021, 19(1):396
S2407	Curcumol	Curcumol is a pure monomer isolated from Rhizoma Curcumaeis with antitumor activities.	J Ethnopharmacol, 2021, 280:114413 Cell Prolif, 2020, 53(3):e12762 Phytother Res, 2020, 10.1002/ptr.6968
S2686	NVP-BSK805 2HCl	NVP-BSK805 2HCl is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM,>20-fold selectivity towards JAK1, JAK3 and TYK2.	Sci Rep, 2022, 12(1):7 Elife, 2021, 10e60646 Am J Transplant, 2021, 21(7):2360-2371
S2692	TG101209	TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET (c-RET) with IC50 of 25 nM and 17 nM in cell-free assays, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.	Sci Rep, 2022, 12(1):7 Cell Death Discov, 2021, 7(1):268 Cell Death Discov, 2021, 7(1):268
S2736	Fedratinib (TG101348)	Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. Phase 2.	Sci Rep, 2022, 12(1):7 Cell, 2021, 184(2):334-351.e20 Mol Cell, 2021, S1097-2765(21)01068-6
S2789	Tofacitinib (CP-690550)	Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.	Blood, 2022, blood.2021012366 Nat Commun, 2021, 12(1):5183 Clin Cancer Res, 2021, clincanres.1978.2021
S2796	WP1066	WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. WP1066 induces apoptosis. Phase 1.	Cell Death Differ, 2021, 10.1038/s41418-021-00880-2 J Cell Physiol, 2021, 10.1002/jcp.30373 Front Oncol, 2021, 11:705547
S2806	CEP-33779	CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.	Sci Rep, 2022, 12(1):7 Nat Med, 2020, 10.1038/s41591-020-0926-0 Carcinogenesis, 2020, 41(7):993-1004
S2851	Baricitinib (INCB028050)	Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19. Phase 3.	Blood, 2022, blood.2021012366 Immunity, 2021, 54(11):2514-2530.e7 Mol Syst Biol, 2021, 17(9):e10426
S2867	WHI-P154	WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.	Sci Rep, 2022, 12(1):7 Am J Transplant, 2021, 21(7):2360-2371 J Med Chem, 2020, 31
S2902	S-Ruxolitinib (INCB018424)	S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.	Nat Commun, 2021, 12(1):2346 PLoS Pathog, 2021, 17(12):e1010174 Nat Med, 2020, 10.1038/s41591-020-0926-0
S3267	Kaempferol-3-O-rutinoside	Kaempferol-3-O-rutinoside (Nicotiflorin, Nikotoflorin, Kaempferol 3-O-β-rutinoside), a flavonoid extracted from Carthamus tinctorius, alters the shape and structure of injured neurons, decreases the number of apoptotic cells, down-regulates expression of p-JAK2, p-STAT3, caspase-3, and Bax and decreases Bax immunoredactivity, and increases Bcl-2 protein expression and immunoreactivity.
S3566^New	Cerdulatinib (PRT062070)	Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
S5001	Tofacitinib (CP-690550) Citrate	Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.	Blood, 2022, blood.2021012366 Mol Neurodegener, 2022, 17(1):7 Nat Commun, 2021, 12(1):5183
S5243	Ruxolitinib Phosphate	Ruxolitinib Phosphate (INCB018424, INC424) is the phosphate salt form of Ruxolitinib. Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.	Blood, 2022, blood.2021012366 Mol Neurodegener, 2022, 17(1):7 J Exp Clin Cancer Res, 2022, 41(1):10
S5554	Lanatoside C	Lanatoside C is a cardiac glycoside with antiviral and anti-tumor activity. Lanatoside C induces G2/M cell cycle arrest and induces autophagy and apoptosis via attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways.
S5588	Creatine	Creatine (Methylguanidoacetic acid) is a nitrogenous organic acid that occurs naturally in vertebrates. It facilitates the recycling of adenosine triphosphate (ATP) primarily in muscle and brain tissue.Creatine can inhibits the JAK-STAT1 signal transmission by inhibiting the interaction of IFN-γ receptors with JAK2 in an ATP-independent manner, thereby inhibiting downstream pro-inflammatory gene expression.	Cancer Cell, 2021, S1535-6108(21)00445-1 Histochem Cell Biol, 2021, 156(3):227-237
S5754	Baricitinib phosphate	Baricitinib phosphate (INCB-028050, LY-3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19.	J Immunother Cancer, 2021, 9(6)e002305 Front Immunol, 2021, 12:720697 J Cell Mol Med, 2021, 10.1111/jcmm.16684
S5902	1,2,3,4,5,6-Hexabromocyclohexane	1,2,3,4,5,6-Hexabromocyclohexane (NSC7908) is a potent inhibitor of JAK2 tyrosine kinase autophosphorylation with IC50 value to be estimated in low micromolar range.	Cell Tissue Res, 2016, 364(2):395-404
S5903	JANEX-1	JANEX-1 (WHI-P131) is a small molecule inhibitor of JAK3 that selectively inhibits JAK3 at an IC50 of 78 µM without altering the activity of JAK1 or JAK2, or any other protein tyrosine kinases (IC50 ≥ 350 µM).	Exp Biol Med (Maywood), 2020, 1535370220942470
S5904	WHI-P97	WHI-P97 is a potent inhibitor of JAK-3 with an estimated Ki value of 0.09 μM in modeling studies and a measured IC50 value of 2.5 μM in EGFR kinase inhibition assays.	J Med Chem, 2020, 31
S5917	Solcitinib	Solcitinib (GLPG0778, GSK2586184) is an inhibitor of JAK1 with an IC50 of 8-9 nM, and shows 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively.	Cancer Lett, 2021, 510:37-47 bioRxiv, 2021, N/A Front Immunol, 2020, 11:1303
S6521	WHI-P258	WHI-P258 is an inhibitor of JAK3 with Ki value of 72 μM.
S6524	NSC 42834	NSC42834 (JAK2 Inhibitor V, Z3) is an inhibitor of the autophosphorylation of wild type and V617F mutant forms of JAK2 with IC50 values between 10 and 30 μM.
S6789^New	JAK Inhibitor I (Pyridone 6)	JAK Inhibitor I (Pyridone 6, CMP 6, Compound 6) is a pan-JAK inhibitor with IC50s of 1 nM, 1 nM, 5 nM and 15 nM for JAK2, TYK2, JAK3 and JAK1, respectively.	Cell Chem Biol, 2021, S2451-9456(21)00303-2
S6899	Licochalcone D	Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. Licochalcone D inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone D inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. Licochalcone D also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
S6919	Brevilin A	Brevilin A (6-O-Angeloylplenolina), a sesquiterpene lactone isolated from Centipeda minima, is a selective inhibitor of STAT3 and attenuates the JAKs activity by blocking the JAKs tyrosine kinase domain JH1. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation.
S7036	XL019	XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.	Sci Rep, 2022, 12(1):7 Molecules, 2021, 26(3)606 J Med Chem, 2020, 31
S7119	Go6976	Go6976 (PD406976) is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.	Cell Chem Biol, 2021, S2451-9456(21)00303-2 Biochimie, 2021, 184:8-17 J Cell Physiol, 2020, 10.1002/jcp.30207
S7137	GLPG0634 analogue	GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.
S7144	BMS-911543	BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.	NPJ Precis Oncol, 2021, 5(1):75 Oncogene, 2019, 38(9):1477-1488 J Pathol, 2019, 10.1002/path.5280
S7198	BIO	BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.	Development, 2022, 149(1)dev200021 Sci Rep, 2022, 12(1):7 Mol Cell, 2021, 81(18):3803-3819.e7
S7259	FLLL32	FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.	Int Immunopharmacol, 2021, 92:107304 Onco Targets Ther, 2021, 14:379-392 Onco Targets Ther, 2020, 12;13:2215-2224
S7541	Decernotinib (VX-509)	Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with K_i of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3.	Proc Natl Acad Sci U S A, 2022, 119(3)e2114134119 Sci Rep, 2022, 12(1):7 JCI Insight, 2021, 6(7)142205
S7605	Filgotinib (GLPG0634)	Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.	Sci Rep, 2022, 12(1):7 J Cell Biol, 2021, 220(9)e202004114 Cell Death Dis, 2021, 12(10):864
S7634	Cerdulatinib (PRT062070) hydrochloride	Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.	Cancer Lett, 2021, 512:28-37 Mol Carcinog, 2021, 60(7):481-496 Hum Cell, 2021, 10.1007/s13577-021-00579-z
S7650	Peficitinib (ASP015K)	Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
S7812	Itacitinib (INCB39110)	Itacitinib(INCB39110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.
S8004	ZM 39923 HCl	ZM 39923 HCl is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.	Sci Rep, 2022, 12(1):7 Carcinogenesis, 2020, 41(7):993-1004 Int J Biol Sci, 2019, 15(9):1882-1891
S8057	Pacritinib (SB1518)	Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.	Sci Rep, 2022, 12(1):7 Cancer Res, 2021, canres.2125.2020 Cancer Sci, 2021, 112(11):4711-4721
S8152^New	Cucurbitacin I	Cucurbitacin-I (Elatericin B, JSI 124, NSC 521777), a natural cell-permeable triterpenoid isolated from Cucurbitaceae, is a novel selective inhibitor of JAK2/STAT3.
S8162	Upadacitinib (ABT-494)	Upadacitinib (ABT-494) is a selective JAK1 inhibitor which demonstrates activity against JAK1 (0.045 μM) and JAK2 (0.109 μM), with > 40 fold selectivity over JAK3 (2.1 μM) and 100 fold selectivity over TYK2 (4.7 μM) as compared to JAK1.	J Clin Med, 2021, 10(7)1431 Platelets, 2021, 1-12 Drugs Context, 2020, 92020-8-5
S8195	Oclacitinib maleate	Oclacitinib maleate (PF-03394197) is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM. It does not inhibit a panel of 38 non-JAK kinases.	Sci Rep, 2022, 12(1):7 Platelets, 2021, 1-12 Carcinogenesis, 2020, 41(7):993-1004
S8538	Ritlecitinib (PF-06651600)	Ritlecitinib (PF-06651600) is a potent and irreversible JAK3-selective inhibitor with an IC50 of 33.1 nM but without activity (IC50 > 10 000 nM) against JAK1, JAK2, and TYK2.
S8541	FM-381	FM-381 is a JAK3 specific reversible covalent inhibitor with IC50 of 127 pM for JAK3 and demonstrates 400-, 2,700- and 3,600-fold selectivity over JAK1, JAK2, and TYK2, respectively.	Commun Biol, 2020, 3:8
S8684	Selective JAK3 inhibitor 1	Selective JAK3 inhibitor 1 is an irreversible JAK3 inhibitor with Ki values of 0.07 nM, 320 nM, 740 nM for JAK3, JAK1 and JAK2 respectively. It is also selective over the other kinases possessing a cysteine in the same region as JAK3, such as BMX, EGFR, ITK, and BTK.
S8765	Abrocitinib (PF-04965842)	Abrocitinib (PF-04965842) is a potent JAK1 inhibitor with IC50s of 29 nM, 803 nM, > 10 000 nM and 1250 nM for JAK1, JAK2, JAK3 and tyrosine kinase (TYK) 2, respectively.	Int J Med Sci, 2020, 18;17(5):609-619 Cell Death Dis, 2019, 10(4):319 Biochem Biophys Res Commun, 2018, 501(3):791-799
S8804	Brepocitinib (PF-06700841)	Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.
S8879	Deucravacitinib (BMS-986165)	Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.
S9676	Ropsacitinib (PF-06826647)	Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO).
A5159	JAK1 Rabbit Recombinant mAb	JAK1 Rabbit Recombinant mAb detects endogenous level of JAK1.
E0011^New	Linderalactone	Linderalactone inhibits human lung cancer growth by modulating the expression of apoptosis-related proteins (Bax and Bcl-2) with an IC50 of 15 µM in A-549 cells. Linderalactone induces G2/M cell cycle arrest and could also suppress the JAK/STAT signalling pathway. Linderalactone can be isolated from Radix linderae.
S0374	GDC046	GDC046 (Compound 3) is a potent, selective, and orally bioavailable inhibitor of TYK2 with Ki of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM for TYK2, JAK1, JAK2, and JAK3, respectively.
S0384	RO495	RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).
S0391	TG-89	TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM.
S0437	SAR-20347	SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling.
S0871	Gusacitinib (ASN-002)	Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
S0918	Ginkgolic acid C17:1	Ginkgolic acid C17:1 (GAC 17:1) inhibits constitutive activation of STAT3 through the abrogation of upstream JAK2 and Src. Ginkgolic acid C17:1 can induce the substantial expression of PTEN and SHP-1. Ginkgolic acid C17:1 induces apoptosis of tumor cells.
S0981	BD750	BD750 is an immunosuppressant and a dual inhibitor of JAK3 and STAT5 that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.5 μM and 1.1 μM for mouse and human T-cell proliferation, respectively.
S1134	AT9283	AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM in cell-free assays; also potent to Aurora A/B, Abl1(T315I). Phase 2.	Sci Rep, 2022, 12(1):7 Mol Syst Biol, 2021, 17(9):e10426 Cancers (Basel), 2021, 13(6)1205
S1143	AG-490 (Tyrphostin B42)	AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.	Nat Commun, 2021, 12(1):6891 Cell Mol Life Sci, 2021, 10.1007/s00018-021-03997-2 Front Oncol, 2021, 11:650052
S1378	Ruxolitinib (INCB018424)	Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.	Blood, 2022, blood.2021012366 Mol Neurodegener, 2022, 17(1):7 J Exp Clin Cancer Res, 2022, 41(1):10
S2162	AZD1480	AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.	Mol Neurodegener, 2022, 17(1):7 Sci Rep, 2022, 12(1):7 Immunity, 2021, 54(11):2514-2530.e7
S2179	Gandotinib (LY2784544)	Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.	Sci Rep, 2022, 12(1):7 BMC Cancer, 2021, 21(1):1213 Molecules, 2021, 26(3)606
S2214	AZ 960	AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and K_i of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3. AZ 960 induces apoptosis and growth arrest.	BMC Cancer, 2021, 21(1):1213 Carcinogenesis, 2020, 41(7):993-1004 Nat Commun, 2019, 10(1):716
S2219	Momelotinib (CYT387)	Momelotinib (CYT387, LM-1149 , CYT11387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Momelotinib (CYT387) induces apoptosis and autophagy. Phase 3.	Cell Stem Cell, 2021, S1934-5909(21)00344-1 Cancer Res, 2021, canres.0955.2021 J Transl Med, 2021, 19(1):396
S2407	Curcumol	Curcumol is a pure monomer isolated from Rhizoma Curcumaeis with antitumor activities.	J Ethnopharmacol, 2021, 280:114413 Cell Prolif, 2020, 53(3):e12762 Phytother Res, 2020, 10.1002/ptr.6968
S2686	NVP-BSK805 2HCl	NVP-BSK805 2HCl is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM,>20-fold selectivity towards JAK1, JAK3 and TYK2.	Sci Rep, 2022, 12(1):7 Elife, 2021, 10e60646 Am J Transplant, 2021, 21(7):2360-2371
S2692	TG101209	TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET (c-RET) with IC50 of 25 nM and 17 nM in cell-free assays, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.	Sci Rep, 2022, 12(1):7 Cell Death Discov, 2021, 7(1):268 Cell Death Discov, 2021, 7(1):268
S2736	Fedratinib (TG101348)	Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. Phase 2.	Sci Rep, 2022, 12(1):7 Cell, 2021, 184(2):334-351.e20 Mol Cell, 2021, S1097-2765(21)01068-6
S2789	Tofacitinib (CP-690550)	Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.	Blood, 2022, blood.2021012366 Nat Commun, 2021, 12(1):5183 Clin Cancer Res, 2021, clincanres.1978.2021
S2796	WP1066	WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. WP1066 induces apoptosis. Phase 1.	Cell Death Differ, 2021, 10.1038/s41418-021-00880-2 J Cell Physiol, 2021, 10.1002/jcp.30373 Front Oncol, 2021, 11:705547
S2806	CEP-33779	CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.	Sci Rep, 2022, 12(1):7 Nat Med, 2020, 10.1038/s41591-020-0926-0 Carcinogenesis, 2020, 41(7):993-1004
S2851	Baricitinib (INCB028050)	Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19. Phase 3.	Blood, 2022, blood.2021012366 Immunity, 2021, 54(11):2514-2530.e7 Mol Syst Biol, 2021, 17(9):e10426
S2867	WHI-P154	WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.	Sci Rep, 2022, 12(1):7 Am J Transplant, 2021, 21(7):2360-2371 J Med Chem, 2020, 31
S2902	S-Ruxolitinib (INCB018424)	S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.	Nat Commun, 2021, 12(1):2346 PLoS Pathog, 2021, 17(12):e1010174 Nat Med, 2020, 10.1038/s41591-020-0926-0
S3267	Kaempferol-3-O-rutinoside	Kaempferol-3-O-rutinoside (Nicotiflorin, Nikotoflorin, Kaempferol 3-O-β-rutinoside), a flavonoid extracted from Carthamus tinctorius, alters the shape and structure of injured neurons, decreases the number of apoptotic cells, down-regulates expression of p-JAK2, p-STAT3, caspase-3, and Bax and decreases Bax immunoredactivity, and increases Bcl-2 protein expression and immunoreactivity.
S3566^New	Cerdulatinib (PRT062070)	Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
S5001	Tofacitinib (CP-690550) Citrate	Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.	Blood, 2022, blood.2021012366 Mol Neurodegener, 2022, 17(1):7 Nat Commun, 2021, 12(1):5183
S5243	Ruxolitinib Phosphate	Ruxolitinib Phosphate (INCB018424, INC424) is the phosphate salt form of Ruxolitinib. Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.	Blood, 2022, blood.2021012366 Mol Neurodegener, 2022, 17(1):7 J Exp Clin Cancer Res, 2022, 41(1):10
S5554	Lanatoside C	Lanatoside C is a cardiac glycoside with antiviral and anti-tumor activity. Lanatoside C induces G2/M cell cycle arrest and induces autophagy and apoptosis via attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways.
S5588	Creatine	Creatine (Methylguanidoacetic acid) is a nitrogenous organic acid that occurs naturally in vertebrates. It facilitates the recycling of adenosine triphosphate (ATP) primarily in muscle and brain tissue.Creatine can inhibits the JAK-STAT1 signal transmission by inhibiting the interaction of IFN-γ receptors with JAK2 in an ATP-independent manner, thereby inhibiting downstream pro-inflammatory gene expression.	Cancer Cell, 2021, S1535-6108(21)00445-1 Histochem Cell Biol, 2021, 156(3):227-237
S5754	Baricitinib phosphate	Baricitinib phosphate (INCB-028050, LY-3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19.	J Immunother Cancer, 2021, 9(6)e002305 Front Immunol, 2021, 12:720697 J Cell Mol Med, 2021, 10.1111/jcmm.16684
S5902	1,2,3,4,5,6-Hexabromocyclohexane	1,2,3,4,5,6-Hexabromocyclohexane (NSC7908) is a potent inhibitor of JAK2 tyrosine kinase autophosphorylation with IC50 value to be estimated in low micromolar range.	Cell Tissue Res, 2016, 364(2):395-404
S5903	JANEX-1	JANEX-1 (WHI-P131) is a small molecule inhibitor of JAK3 that selectively inhibits JAK3 at an IC50 of 78 µM without altering the activity of JAK1 or JAK2, or any other protein tyrosine kinases (IC50 ≥ 350 µM).	Exp Biol Med (Maywood), 2020, 1535370220942470
S5904	WHI-P97	WHI-P97 is a potent inhibitor of JAK-3 with an estimated Ki value of 0.09 μM in modeling studies and a measured IC50 value of 2.5 μM in EGFR kinase inhibition assays.	J Med Chem, 2020, 31
S5917	Solcitinib	Solcitinib (GLPG0778, GSK2586184) is an inhibitor of JAK1 with an IC50 of 8-9 nM, and shows 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively.	Cancer Lett, 2021, 510:37-47 bioRxiv, 2021, N/A Front Immunol, 2020, 11:1303
S6521	WHI-P258	WHI-P258 is an inhibitor of JAK3 with Ki value of 72 μM.
S6524	NSC 42834	NSC42834 (JAK2 Inhibitor V, Z3) is an inhibitor of the autophosphorylation of wild type and V617F mutant forms of JAK2 with IC50 values between 10 and 30 μM.
S6789^New	JAK Inhibitor I (Pyridone 6)	JAK Inhibitor I (Pyridone 6, CMP 6, Compound 6) is a pan-JAK inhibitor with IC50s of 1 nM, 1 nM, 5 nM and 15 nM for JAK2, TYK2, JAK3 and JAK1, respectively.	Cell Chem Biol, 2021, S2451-9456(21)00303-2
S6899	Licochalcone D	Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. Licochalcone D inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone D inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. Licochalcone D also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
S6919	Brevilin A	Brevilin A (6-O-Angeloylplenolina), a sesquiterpene lactone isolated from Centipeda minima, is a selective inhibitor of STAT3 and attenuates the JAKs activity by blocking the JAKs tyrosine kinase domain JH1. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation.
S7036	XL019	XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.	Sci Rep, 2022, 12(1):7 Molecules, 2021, 26(3)606 J Med Chem, 2020, 31
S7119	Go6976	Go6976 (PD406976) is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.	Cell Chem Biol, 2021, S2451-9456(21)00303-2 Biochimie, 2021, 184:8-17 J Cell Physiol, 2020, 10.1002/jcp.30207
S7137	GLPG0634 analogue	GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.
S7144	BMS-911543	BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.	NPJ Precis Oncol, 2021, 5(1):75 Oncogene, 2019, 38(9):1477-1488 J Pathol, 2019, 10.1002/path.5280
S7198	BIO	BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.	Development, 2022, 149(1)dev200021 Sci Rep, 2022, 12(1):7 Mol Cell, 2021, 81(18):3803-3819.e7
S7259	FLLL32	FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.	Int Immunopharmacol, 2021, 92:107304 Onco Targets Ther, 2021, 14:379-392 Onco Targets Ther, 2020, 12;13:2215-2224
S7541	Decernotinib (VX-509)	Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with K_i of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3.	Proc Natl Acad Sci U S A, 2022, 119(3)e2114134119 Sci Rep, 2022, 12(1):7 JCI Insight, 2021, 6(7)142205
S7605	Filgotinib (GLPG0634)	Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.	Sci Rep, 2022, 12(1):7 J Cell Biol, 2021, 220(9)e202004114 Cell Death Dis, 2021, 12(10):864
S7634	Cerdulatinib (PRT062070) hydrochloride	Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.	Cancer Lett, 2021, 512:28-37 Mol Carcinog, 2021, 60(7):481-496 Hum Cell, 2021, 10.1007/s13577-021-00579-z
S7650	Peficitinib (ASP015K)	Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
S7812	Itacitinib (INCB39110)	Itacitinib(INCB39110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.
S8004	ZM 39923 HCl	ZM 39923 HCl is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.	Sci Rep, 2022, 12(1):7 Carcinogenesis, 2020, 41(7):993-1004 Int J Biol Sci, 2019, 15(9):1882-1891
S8057	Pacritinib (SB1518)	Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.	Sci Rep, 2022, 12(1):7 Cancer Res, 2021, canres.2125.2020 Cancer Sci, 2021, 112(11):4711-4721
S8152^New	Cucurbitacin I	Cucurbitacin-I (Elatericin B, JSI 124, NSC 521777), a natural cell-permeable triterpenoid isolated from Cucurbitaceae, is a novel selective inhibitor of JAK2/STAT3.
S8162	Upadacitinib (ABT-494)	Upadacitinib (ABT-494) is a selective JAK1 inhibitor which demonstrates activity against JAK1 (0.045 μM) and JAK2 (0.109 μM), with > 40 fold selectivity over JAK3 (2.1 μM) and 100 fold selectivity over TYK2 (4.7 μM) as compared to JAK1.	J Clin Med, 2021, 10(7)1431 Platelets, 2021, 1-12 Drugs Context, 2020, 92020-8-5
S8195	Oclacitinib maleate	Oclacitinib maleate (PF-03394197) is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM. It does not inhibit a panel of 38 non-JAK kinases.	Sci Rep, 2022, 12(1):7 Platelets, 2021, 1-12 Carcinogenesis, 2020, 41(7):993-1004
S8538	Ritlecitinib (PF-06651600)	Ritlecitinib (PF-06651600) is a potent and irreversible JAK3-selective inhibitor with an IC50 of 33.1 nM but without activity (IC50 > 10 000 nM) against JAK1, JAK2, and TYK2.
S8541	FM-381	FM-381 is a JAK3 specific reversible covalent inhibitor with IC50 of 127 pM for JAK3 and demonstrates 400-, 2,700- and 3,600-fold selectivity over JAK1, JAK2, and TYK2, respectively.	Commun Biol, 2020, 3:8
S8684	Selective JAK3 inhibitor 1	Selective JAK3 inhibitor 1 is an irreversible JAK3 inhibitor with Ki values of 0.07 nM, 320 nM, 740 nM for JAK3, JAK1 and JAK2 respectively. It is also selective over the other kinases possessing a cysteine in the same region as JAK3, such as BMX, EGFR, ITK, and BTK.
S8765	Abrocitinib (PF-04965842)	Abrocitinib (PF-04965842) is a potent JAK1 inhibitor with IC50s of 29 nM, 803 nM, > 10 000 nM and 1250 nM for JAK1, JAK2, JAK3 and tyrosine kinase (TYK) 2, respectively.	Int J Med Sci, 2020, 18;17(5):609-619 Cell Death Dis, 2019, 10(4):319 Biochem Biophys Res Commun, 2018, 501(3):791-799
S8804	Brepocitinib (PF-06700841)	Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.
S8879	Deucravacitinib (BMS-986165)	Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.
S9676	Ropsacitinib (PF-06826647)	Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO).
A5159	JAK1 Rabbit Recombinant mAb	JAK1 Rabbit Recombinant mAb detects endogenous level of JAK1.
E0011^New	Linderalactone	Linderalactone inhibits human lung cancer growth by modulating the expression of apoptosis-related proteins (Bax and Bcl-2) with an IC50 of 15 µM in A-549 cells. Linderalactone induces G2/M cell cycle arrest and could also suppress the JAK/STAT signalling pathway. Linderalactone can be isolated from Radix linderae.
S3566^New	Cerdulatinib (PRT062070)	Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
S6789^New	JAK Inhibitor I (Pyridone 6)	JAK Inhibitor I (Pyridone 6, CMP 6, Compound 6) is a pan-JAK inhibitor with IC50s of 1 nM, 1 nM, 5 nM and 15 nM for JAK2, TYK2, JAK3 and JAK1, respectively.	Cell Chem Biol, 2021, S2451-9456(21)00303-2
S8152^New	Cucurbitacin I	Cucurbitacin-I (Elatericin B, JSI 124, NSC 521777), a natural cell-permeable triterpenoid isolated from Cucurbitaceae, is a novel selective inhibitor of JAK2/STAT3.